Laura Dawson, MD

Articles

Stereotactic Body Radiotherapy Can Benefit Some Patients with HCC

June 19th 2023

Laura A. Dawson, MD, FRCPC, discusses key takeaways from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in patients with hepatocellular carcinoma.

NRG/RTOG 1112 Study Evaluates SBRT Plus Sorafenib for Hepatocellular Carcinoma

Laura Dawson, MD

March 22nd 2023

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

Sorafenib Plus SBRT Shows Improvement in QOL Measure for HCC

Laura Dawson, MD

February 13th 2023

Laura A. Dawson, MD, FRCPC, discusses quality-of-life outcomes from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib versus sorafenib alone in hepatocellular carcinoma.

Results From the Phase 3 NRG/RTOG 1112 Study of Sorafenib in HCC

Laura Dawson, MD

January 20th 2023

Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.

Screening and Prevention of HCC

Laura Dawson, MD

April 7th 2015

Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).